Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

NCT04919811 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT04919811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04919811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2021
Completion date
December 31, 2027
Enrollment
217 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer